Awarding the innovative and excellent research in Oncology and developing conference training and informative materials for health professionals, patients and journalists are some of the activities that will launch the new Chair Gilead Innovation in Oncology, the first academic initiative of this subject of the Cancer Center Clínica Universidad de Navarra (CCUN).

Paloma Grau, Vice President of research and Sustainability of the University of Navarra, and Marisa Alvarez, Medical Director of Gilead Sciences, have signed the partnership agreement between the two institutions for the implementation of the Chair, whose manager will be Dr. Antonio Gonzalez, director of the CCUN.

In addition to these initiatives, Chair includes training activities on antibody-drug conjugates (ADCs), a new generation of monoclonal antibodies that act in a targeted manner against cancer cells, avoiding damage to other healthy cells. Thus, a guide of training will be published for healthcare professionals in this field. 

The Vice President Paloma Grau recalled that "the 2025 Strategy of the University of Navarra is committed to research in personalized medicine, in which progress against cancer is a priority line of research" and Marisa Álvarez highlighted "the importance of launching the first Chair of Oncology with a center of reference letter as the CCUN. For Gilead it is a day of celebration, convinced that with this initiative we reinforce our commitment to continuous training and innovation, essential pieces to bring hope to patients". 

Dr. Antonio Gonzalez stressed that the new Chair promotes "the excellent research , the training of professionals and the knowledge dissemination, essential activities of the CCUN, a comprehensive cancer center, which brings together all the healthcare, research and professor activities in Oncology of the University of Navarra to be more effective in our task of contributing to cure cancer as soon as possible".